BIOMAT Database Logo BIOMAT Database Logo

Effects of subchronic treatment with selegiline on L-DOPA-induced increase in extracellular dopamine level in rat striatum. 2006

Kouichi Adachi, and Hideto Miwa, and Haruko Kusumoto, and Seiichiro Shimazu, and Tomoyoshi Kondo
Department of Neurology, Wakayama Medical University, Wakayama, Japan.

Selegiline is used an adjunct to L-DOPA therapy. We investigated extracellular striatal dopamine (DA) level in awake rats treated with L-DOPA and/or selegiline using a microdialysis method. Rats given 10 mg/kg, i.p. per day selegiline for 7 days were administered with a single dose of 100 mg/kg, i.p. L-DOPA 0 (3 h), 1, 3, 7, 14, 21, or 28 days after the last selegiline treatment. Carbidopa was administered 0.5 h before L-DOPA administration. The significant increase in basal DA level before L-DOPA treatment persisted until 1 day after the last selegiline treatment, and the significant decrease in basal DOPAC level persisted for more than 28 days. Thus, selegiline affected DA catabolism for more than 28 days. Total monoamine oxidase (MAO) and MAO-B activities at day 0 decreased by 22% and 5.7%, respectively. The significant enhancement of L-DOPA-induced increase in DA level was observed until 3 days after the last selegiline treatment. Next, the effects of reducing L-DOPA dose by 25% were examined 3 h after the last selegiline treatment. A dose-dependent decrease in DA level was observed, indicating that DA level in selegiline-treated rats can be controlled by L-DOPA dose.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005110 Extracellular Space Interstitial space between cells, occupied by INTERSTITIAL FLUID as well as amorphous and fibrous substances. For organisms with a CELL WALL, the extracellular space includes everything outside of the CELL MEMBRANE including the PERIPLASM and the cell wall. Intercellular Space,Extracellular Spaces,Intercellular Spaces,Space, Extracellular,Space, Intercellular,Spaces, Extracellular,Spaces, Intercellular

Related Publications

Kouichi Adachi, and Hideto Miwa, and Haruko Kusumoto, and Seiichiro Shimazu, and Tomoyoshi Kondo
Neostigmine influences the L-dopa-induced extracellular dopamine levels in the striatum.
February 2000, Brain research,
Kouichi Adachi, and Hideto Miwa, and Haruko Kusumoto, and Seiichiro Shimazu, and Tomoyoshi Kondo
Histamine H(3) receptor ligands modulate L-dopa-evoked behavioral responses and L-dopa derived extracellular dopamine in dopamine-denervated rat striatum.
January 2008, Neurotoxicity research,
Kouichi Adachi, and Hideto Miwa, and Haruko Kusumoto, and Seiichiro Shimazu, and Tomoyoshi Kondo
Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats.
August 1990, Brain research,
Kouichi Adachi, and Hideto Miwa, and Haruko Kusumoto, and Seiichiro Shimazu, and Tomoyoshi Kondo
Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
January 1999, Journal of neural transmission (Vienna, Austria : 1996),
Kouichi Adachi, and Hideto Miwa, and Haruko Kusumoto, and Seiichiro Shimazu, and Tomoyoshi Kondo
The effects of L-dopa on in vitro dopamine release from striatum.
February 1990, Brain research,
Kouichi Adachi, and Hideto Miwa, and Haruko Kusumoto, and Seiichiro Shimazu, and Tomoyoshi Kondo
[Effect of subchronic administration of tolcapone on release of striatum dopamine and its metabolites induced by L-DOPA and carbidopa].
February 1998, Biulleten' eksperimental'noi biologii i meditsiny,
Kouichi Adachi, and Hideto Miwa, and Haruko Kusumoto, and Seiichiro Shimazu, and Tomoyoshi Kondo
Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. II. Effect of L-dopa on dopamine and dopamine metabolite concentration in rat striatum.
December 1994, Biological & pharmaceutical bulletin,
Kouichi Adachi, and Hideto Miwa, and Haruko Kusumoto, and Seiichiro Shimazu, and Tomoyoshi Kondo
The site of dopamine formation in rat striatum after L-dopa administration.
April 1981, The Journal of pharmacology and experimental therapeutics,
Kouichi Adachi, and Hideto Miwa, and Haruko Kusumoto, and Seiichiro Shimazu, and Tomoyoshi Kondo
Re-evaluation of the L-dopa loading effect on dopamine metabolism in rat striatum.
February 1986, The Journal of pharmacy and pharmacology,
Kouichi Adachi, and Hideto Miwa, and Haruko Kusumoto, and Seiichiro Shimazu, and Tomoyoshi Kondo
Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum.
March 2002, Journal of neural transmission (Vienna, Austria : 1996),
Copied contents to your clipboard!